256 related articles for article (PubMed ID: 9797203)
1. Resistance to human immunodeficiency virus type 1 protease inhibitors.
Boden D; Markowitz M
Antimicrob Agents Chemother; 1998 Nov; 42(11):2775-83. PubMed ID: 9797203
[No Abstract] [Full Text] [Related]
2. [Resistance to protease inhibitors].
Clotet B; Martínez-Picado J; Arrizabalaga J; Ruiz L
Enferm Infecc Microbiol Clin; 2001 Feb; 19(Monografico):34-41. PubMed ID: 11428058
[No Abstract] [Full Text] [Related]
3. Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells.
Schütt M; Zhou J; Meier M; Klein HH
J Endocrinol; 2004 Dec; 183(3):445-54. PubMed ID: 15590971
[TBL] [Abstract][Full Text] [Related]
4. The utility of inhibitory quotients in determining the relative potency of protease inhibitors.
Piliero PJ
AIDS; 2002 Mar; 16(5):799-800. PubMed ID: 11964541
[No Abstract] [Full Text] [Related]
5. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.
Granfors MT; Wang JS; Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):79-85. PubMed ID: 16433896
[TBL] [Abstract][Full Text] [Related]
6. Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture.
Perloff MD; von Moltke LL; Fahey JM; Daily JP; Greenblatt DJ
AIDS; 2000 Jun; 14(9):1287-9. PubMed ID: 10894301
[No Abstract] [Full Text] [Related]
7. HIV protease inhibitors.
Carr A; Cooper DA
AIDS; 1996; 10 Suppl A():S151-7. PubMed ID: 8883623
[No Abstract] [Full Text] [Related]
8. Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.
Ntemgwa M; Brenner BG; Oliveira M; Moisi D; Wainberg MA
Antimicrob Agents Chemother; 2007 Feb; 51(2):604-10. PubMed ID: 17116674
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 protease mutations and protease inhibitor cross-resistance.
Rhee SY; Taylor J; Fessel WJ; Kaufman D; Towner W; Troia P; Ruane P; Hellinger J; Shirvani V; Zolopa A; Shafer RW
Antimicrob Agents Chemother; 2010 Oct; 54(10):4253-61. PubMed ID: 20660676
[TBL] [Abstract][Full Text] [Related]
10. Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir.
Pfister M; Labbé L; Lu JF; Hammer SM; Mellors J; Bennett KK; Rosenkranz S; Sheiner LB;
Clin Pharmacol Ther; 2002 Aug; 72(2):133-41. PubMed ID: 12189360
[TBL] [Abstract][Full Text] [Related]
11. Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
Mo H; Parkin N; Stewart KD; Lu L; Dekhtyar T; Kempf DJ; Molla A
Antimicrob Agents Chemother; 2007 Feb; 51(2):732-5. PubMed ID: 17101675
[TBL] [Abstract][Full Text] [Related]
12. The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients.
Turner D; Schapiro JM; Brenner BG; Wainberg MA
Antivir Ther; 2004 Jun; 9(3):301-14. PubMed ID: 15259893
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir.
Hoetelmans RM; Meenhorst PL; Mulder JW; Burger DM; Koks CH; Beijnen JH
Pharm World Sci; 1997 Aug; 19(4):159-75. PubMed ID: 9297727
[TBL] [Abstract][Full Text] [Related]
14. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2).
Gupta A; Zhang Y; Unadkat JD; Mao Q
J Pharmacol Exp Ther; 2004 Jul; 310(1):334-41. PubMed ID: 15007102
[TBL] [Abstract][Full Text] [Related]
15. Select HIV protease inhibitors alter bone and fat metabolism ex vivo.
Jain RG; Lenhard JM
J Biol Chem; 2002 May; 277(22):19247-50. PubMed ID: 11937496
[TBL] [Abstract][Full Text] [Related]
16. Effects of HIV protease inhibitors on barrier function in the human intestinal cell line HT-29/B6.
Bode H; Schmidt W; Schulzke JD; Fromm M; Riecken EO; Ullrich R
Ann N Y Acad Sci; 2000; 915():117-22. PubMed ID: 11193566
[No Abstract] [Full Text] [Related]
17. Peptidomimetic inhibitors of HIV protease.
Randolph JT; DeGoey DA
Curr Top Med Chem; 2004; 4(10):1079-95. PubMed ID: 15193140
[TBL] [Abstract][Full Text] [Related]
18. In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.
Dierynck I; De Meyer S; Lathouwers E; Vanden Abeele C; Van De Casteele T; Spinosa-Guzman S; de Béthune MP; Picchio G
Antivir Ther; 2010; 15(8):1161-9. PubMed ID: 21149923
[TBL] [Abstract][Full Text] [Related]
19. Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. HIV Variant Working Group.
Pieniazek D; Rayfield M; Hu DJ; Nkengasong J; Wiktor SZ; Downing R; Biryahwaho B; Mastro T; Tanuri A; Soriano V; Lal R; Dondero T
AIDS; 2000 Jul; 14(11):1489-95. PubMed ID: 10983635
[TBL] [Abstract][Full Text] [Related]
20. Differential effect of HIV protease inhibitors on adipogenesis: intracellular ritonavir is not sufficient to inhibit differentiation.
Vernochet C; Azoulay S; Duval D; Guedj R; Ailhaud G; Dani C
AIDS; 2003 Oct; 17(15):2177-80. PubMed ID: 14523274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
